Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION717 intrathecal study in prion disease
jRCT2031230574Phase 1Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 1 trial of ION717 in Prion Disease (PD) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events. Started Mar 2024; status: active, not recruiting.
02
Drugs
ION717
03
Conditions
Prion Disease (PD)
Beyond the preview
Go deeper on jRCT2031230574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230574.